December 4th 2023
Your daily dose of the clinical news you may have missed.
November 28th 2023
Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.
November 9th 2023
The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.
November 8th 2023
NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.
October 3rd 2023
"CKM Syndrome" Defines a Very Wide Target and Medicine is Ready, Says Chiadi Ndumele, MD, PhD, MHS
Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.
Final Pearls and Takeaways for Testing and Managing CKD
Experts wrap up their discussion of emerging chronic kidney disease tests and treatments with key takeaways for providers and patients.
AI CKD Test Clinical Implementation and Provider Pearls
Robert Busch, MD, provides his approach on implementing artificial intelligence (AI) testing for chronic kidney disease and offers success stories of this testing and treatment approach.
Catching CKD Early: Utilizing AI and its Clinical Significance
Experts discuss a new artificial intelligence (AI) tool for earlier staging and management of chronic kidney disease (CKD). They also discuss several studies where this tool was utilized and its overall clinical significance.
Emerging Treatments and Preventative Care for CKD
Dhiren Patel, PharmD, and Robert Busch, MD, discuss emerging technologies to test and treat patients with chronic kidney disease (CKD) and why these treatments are currently being underutilized.
Identifying and Managing CKD With Other Comorbid Conditions
Experts highlight considerations for patients with chronic kidney disease and other comorbid conditions, particularly diabetes, in terms of screening and preventative care.
Filling the Gap: Testing to Identify Early-Stage CKD
Experts discuss key challenges in testing and diagnosing a patient with chronic kidney disease, especially for those who are asymptomatic. In addition, they highlight new screening approaches to accurately identify these patients.
AHA Defines Cardiovascular-Kidney-Metabolic Syndrome, Redefines CVD Risk, Prevention, Management
A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.
Identifying CKD: Screening and Guideline Implementation
Robert Busch, MD, discusses common screening methods to detect chronic kidney disease (CKD) and how he utilizes the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in his practice.
Overview of Chronic Kidney Disease (CKD) and Impact on Patients
Dhiren Patel, PharmD, and Robert Busch, MD, present an overview of chronic kidney disease (CKD) and how it may impact a patient.
In Older Adults with T2D, Clinical Decision Support Tool Can Reduce Hypoglycemia
In adults older than age 65 years with T2D, a simple clinical decision support tool plus shared decision making reduced hypoglycemic episodes by half.
FDA Adds New Warnings to Labeling for Ozempic
The addition of ileus as a potential adverse event associated with the GLP-1 mimetic is not the first required for the class by the regulator.
One or More Cardiac, Renal, or Metabolic Conditions Affect 25% of US Adults
The prevalence of cardiac, renal, and metabolic conditions has significantly increased over 20 years and so has the number of US adults who have all 3.
GLP-1 Mimetics, SGLT-2 Inhibitors Understudied in Black Populations in Pivotal Trials, Benefits Questioned
Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.
Biosimilar Liraglutide Noninferior to Reference Product in Persons with Type 2 Diabetes: Phase 3 Trial
The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.
Abbott, WeightWatchers Announce App Integrating FreeStyle Libre 2 CGM Data
The new app is designed to help persons with diabetes understand how food and activity impact blood glucose levels and to revise behavior accordingly.
Why is Wound Care Falling to Primary Care?
Overscheduled and undertrained, primary care clinicians shoulder a significant portion of the US wound care burden. Author Nima Ahmadi offers a technology-based solution.
Daily Dose: "Night Owls" Less Healthy, at Higher Risk for T2D
PCOS Ups Risk of Maternal, but Not Neonatal Adverse Outcomes in Women with T2D in Pregnancy
Women with PCOS and T2D in pregnancy were at greater risk for high insulin requirements, excess weight gain, and worsening of pregestation hypertension if treated with metformin.
Rise in GLP-1 Mimetic Demand Will Continue as Pluripotency Expands
The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?
Evening Chronotype in Women Linked with Unhealthy Lifestyle, Increased Risk for Type 2 Diabetes
Women with an evening vs morning chronotype were 54% more likely to have unhealthy lifestyles that in turn accounted for a significant increased risk for diabetes.
Cardiorenal Risk Estimates in T2D Mediated by Common Biomarker Response to Canagliflozin
Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.
Daily Dose: Effect of Sotagliflozin on Heart Failure-Related Events
A daily dose of clinical news on Patient Care you may have missed.
Daily Dose: Daily Sugared Drink Intake & Risk of Hepatic Morbidity, Mortality in Postmenopausal Women
Amazon Pharmacy Announces Insulin Discounts with Automatic, Manufacturer-sponsored Coupons
Patients with diabetes will be able to save money when ordering insulin and commonly prescribed products, such as continuous glucose monitors and pumps.
Sotagliflozin Cut Risk by >50% for HF Rehospitalization and CV Death when Started Before Discharge
A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.
Daily Sugared Drink Consumption May Increase Risk of Hepatic Morbidity, Mortality in Older Women
Postmenopausal women who consumed 1 or more sugary drinks daily had a nearly 2-fold increased risk of liver cancer in a study of more than 98 000.
Insulin Prescription Fills Up Following Inflation Reduction Act Cap on Out-of-Pocket Costs
The new policy is helping people who are taking insulin save money and helping others to afford it in the first place, says a study coauthor from the USC Sol Price School of Public Policy .
Mean Weight Loss with Tirzepatide Reaches 26% Across 2 Pivotal Phase 3 Clinical Trials
In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.
Social Determinants of Health and Prevention of Cardiovascular Disease
Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.
2 Clarke Drive Cranbury, NJ 08512